Cefazolin

Generic Name
Cefazolin
Brand Names
-
Drug Type
Small Molecule
Chemical Formula
C14H14N8O4S3
CAS Number
25953-19-9
Unique Ingredient Identifier
IHS69L0Y4T
Background

A semisynthetic cephalosporin analog with broad-spectrum antibiotic action due to inhibition of bacterial cell wall synthesis. It attains high serum levels and is excreted quickly via the urine.

Indication

Mainly used to treat bacterial infections of the skin. It can also be used to treat moderately severe bacterial infections involving the lung, bone, joint, stomach, blood, heart valve, and urinary tract. It is clinically effective against infections caused by staphylococci and streptococci species of Gram positive bacteria. May be used for surgical prophylax...

Associated Conditions
Bacterial Septicemia caused by susceptible Bacterial Infections, Biliary tract infection bacterial caused by susceptible Bacterial Infections, Bone and Joint Infections caused by susceptible Bacterial Infections, Catheter-related Bloodstream Infection (CRBSI) NOS, Community Acquired Pneumonia (CAP), Endocarditis caused by susceptible Bacterial Infections, Genital infection caused by susceptible Bacterial Infections, Osteoarticular Infections, Postoperative Infections, Respiratory Tract Infection Bacterial caused by susceptible Bacterial Infections, Skin and Soft Tissue Infections (SSTIs), Skin and Subcutaneous Tissue Infection caused by susceptible Bacterial Infections, Susceptible infections, Urinary Tract Infection caused by susceptible Bacterial Infections, Perioperative infection, Susceptible Bacterial Infections
Associated Therapies
Antibiotic pre-surgical prophylaxis

Antibiotic Prophylaxis in Orthopaedic Traumatology

Not Applicable
Completed
Conditions
Interventions
First Posted Date
2008-02-08
Last Posted Date
2015-06-12
Lead Sponsor
University of Missouri-Columbia
Target Recruit Count
178
Registration Number
NCT00610987
Locations
🇺🇸

University of Missouri, Columbia, Missouri, United States

Comparison of 2 Cefazolin Prophylactic Protocol in Laryngectomy Patients

Phase 3
Completed
Conditions
First Posted Date
2007-05-01
Last Posted Date
2007-05-01
Lead Sponsor
Tehran University of Medical Sciences
Target Recruit Count
90
Registration Number
NCT00467948
Locations
🇮🇷

Imam khomaini hospital, Tehran, Iran, Islamic Republic of

Timing of Prophylactic Antibiotics for Cesarean Sections

Not Applicable
Completed
Conditions
First Posted Date
2006-05-26
Last Posted Date
2007-09-27
Lead Sponsor
Medical University of South Carolina
Target Recruit Count
350
Registration Number
NCT00330278
Locations
🇺🇸

Medical University of South Carolina, Charleston, South Carolina, United States

© Copyright 2024. All Rights Reserved by MedPath